Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III Trial
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III Trial
Authors
Keywords
-
Journal
JOURNAL OF CLINICAL ONCOLOGY
Volume 39, Issue 27, Pages 3002-3011
Publisher
American Society of Clinical Oncology (ASCO)
Online
2021-06-30
DOI
10.1200/jco.21.00163
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A Phase I dose-escalation, pharmacokinetics and food-effect study of oral donafenib in patients with advanced solid tumours
- (2020) Xiaoyu Li et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
- (2020) Richard S. Finn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Randomized trials and endpoints in advanced HCC: Role of PFS as a surrogate of survival
- (2019) Josep M. Llovet et al. JOURNAL OF HEPATOLOGY
- Insights into the success and failure of systemic therapy for hepatocellular carcinoma
- (2019) Jordi Bruix et al. Nature Reviews Gastroenterology & Hepatology
- A global view of hepatocellular carcinoma: trends, risk, prevention and management
- (2019) Ju Dong Yang et al. Nature Reviews Gastroenterology & Hepatology
- LBA38_PRCheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC)
- (2019) T Yau et al. ANNALS OF ONCOLOGY
- EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
- (2018) Peter R. Galle et al. JOURNAL OF HEPATOLOGY
- Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
- (2018) Masatoshi Kudo et al. LANCET
- Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals
- (2018) Edward M. Russak et al. ANNALS OF PHARMACOTHERAPY
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2018) Freddie Bray et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Ten years of sorafenib in hepatocellular carcinoma: Are there any predictive and/or prognostic markers?
- (2018) Giorgia Marisi et al. WORLD JOURNAL OF GASTROENTEROLOGY
- Cancer statistics in China, 2015
- (2016) Wanqing Chen et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Randomized Controlled Trial of the Prophylactic Effect of Urea-Based Cream on Sorafenib-Associated Hand-Foot Skin Reactions in Patients With Advanced Hepatocellular Carcinoma
- (2015) ZhengGang Ren et al. JOURNAL OF CLINICAL ONCOLOGY
- SEARCH: A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Sorafenib Plus Erlotinib in Patients With Advanced Hepatocellular Carcinoma
- (2015) Andrew X. Zhu et al. JOURNAL OF CLINICAL ONCOLOGY
- Linifanib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: Results of a Randomized Phase III Trial
- (2015) Calin Cainap et al. JOURNAL OF CLINICAL ONCOLOGY
- Attributable Causes of Liver Cancer Mortality and Incidence in China
- (2014) Jin-Hu Fan et al. Asian Pacific Journal of Cancer Prevention
- Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL Study
- (2013) Philip J. Johnson et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized, Multicenter, Open-Label Study of Oxaliplatin Plus Fluorouracil/Leucovorin Versus Doxorubicin As Palliative Chemotherapy in Patients With Advanced Hepatocellular Carcinoma From Asia
- (2013) Shukui Qin et al. JOURNAL OF CLINICAL ONCOLOGY
- Sunitinib Versus Sorafenib in Advanced Hepatocellular Cancer: Results of a Randomized Phase III Trial
- (2013) Ann-Lii Cheng et al. JOURNAL OF CLINICAL ONCOLOGY
- Management of hepatocellular carcinoma: An update
- (2011) Jordi Bruix et al. HEPATOLOGY
- Hepatocellular carcinoma: a global view
- (2010) Ju Dong Yang et al. Nature Reviews Gastroenterology & Hepatology
- Phase I and pharmacokinetic study of sorafenib, an oral multikinase inhibitor, in Japanese patients with advanced refractory solid tumors
- (2008) Hironobu Minami et al. CANCER SCIENCE
- Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
- (2008) Ann-Lii Cheng et al. LANCET ONCOLOGY
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. NEW ENGLAND JOURNAL OF MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now